--- title: "FOXO Tech | 10-Q: FY2026 Q1 Revenue: USD 5.168 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286585490.md" datetime: "2026-05-15T15:01:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286585490.md) - [en](https://longbridge.com/en/news/286585490.md) - [zh-HK](https://longbridge.com/zh-HK/news/286585490.md) --- # FOXO Tech | 10-Q: FY2026 Q1 Revenue: USD 5.168 M Revenue: As of FY2026 Q1, the actual value is USD 5.168 M. EPS: As of FY2026 Q1, the actual value is USD 0. EBIT: As of FY2026 Q1, the actual value is USD 696.28 K. ### Segment Revenue #### Healthcare Segment Net revenues for the three months ended March 31, 2026, were $4,798,551, an increase of $1,637,120 (52%) from $3,161,431 for the same period in 2025, primarily due to increased swing-bed patient services. #### Life Science Services Segment Net revenues were $361,250 for the three months ended March 31, 2026, with no comparable revenue in the prior period as this segment commenced operations on September 19, 2025. #### Labs Segment Net revenues decreased by -$4,103 (-48%) to $4,386 for the three months ended March 31, 2026, from $8,489 for the same period in 2025, primarily consisting of royalty income from Illumina, Inc. #### Total Net Revenues Total net revenues for the three months ended March 31, 2026, were $5,168,036, an increase of $1,998,116 (63.03%) from $3,169,920 for the same period in 2025. ### Operational Metrics #### Healthcare Segment Operating expenses were -$4,504,850 for the three months ended March 31, 2026, compared to -$4,010,379 for the same period in 2025.Segment income was $296,914 for the three months ended March 31, 2026, a significant improvement from a loss of -$844,598 in the prior year, driven by increased net revenues.Noncontrolling interest was $3,213 for the three months ended March 31, 2026, compared to $4,350 for the same period in 2025. #### Life Science Services Segment Operating expenses were -$218,834 for the three months ended March 31, 2026, with no comparable prior period.Segment income was $142,416 for the three months ended March 31, 2026, with no comparable prior period. #### Labs Segment Operating expenses were -$36,756 for the three months ended March 31, 2026, compared to -$31,494 for the same period in 2025.The segment loss increased to -$32,370 for the three months ended March 31, 2026, from a loss of -$23,005 for the same period in 2025. #### Overall Operating Costs and Profitability Direct costs of revenues were $2,534,213 for the three months ended March 31, 2026, compared to $1,903,936 for the same period in 2025, representing 49% and 60% of net revenues, respectively.Research and development expenses were $35,550 for the three months ended March 31, 2026, compared to $30,000 for the same period in 2025.Selling, general and administrative expenses were $2,875,124 for the three months ended March 31, 2026, compared to $2,764,086 for the same period in 2025.Loss from operations improved significantly to -$276,851 for the three months ended March 31, 2026, from -$1,546,980 for the same period in 2025.Interest expense was -$973,135 for the three months ended March 31, 2026, compared to -$889,792 for the same period in 2025.Net loss attributable to FOXO Technologies Inc. was -$1,451,973 for the three months ended March 31, 2026, compared to -$616,458 for the same period in 2025.Adjusted EBITDA improved to -$399,691 for the three months ended March 31, 2026, from -$1,669,629 for the same period in 2025. ### Cash Flow Net cash used in operating activities was -$577,898 for the three months ended March 31, 2026, an improvement from -$1,337,591 for the same period in 2025.Net cash used in investing activities was -$3,995 for the three months ended March 31, 2026, compared to $0 for the same period in 2025.Net cash provided by financing activities was $440,336 for the three months ended March 31, 2026, compared to $1,286,230 for the same period in 2025.Cash and cash equivalents were $65,896 as of March 31, 2026, a decrease from $207,453 as of December 31, 2025. ### Key Financial Position Metrics Working capital deficit was -$27,074,932 as of March 31, 2026, compared to -$25,546,280 as of December 31, 2025.Total debt (net of discounts) was $8,609,877 as of March 31, 2026, compared to $7,292,040 as of December 31, 2025.Goodwill remained stable at $27.8 million as of March 31, 2026, compared to December 31, 2025.Intangible assets, net, were $9,777,041 as of March 31, 2026, compared to $9,770,969 as of December 31, 2025.Total stockholders’ equity was $9,636,114 as of March 31, 2026, a decrease from $11,076,300 as of December 31, 2025. ### Strategic Summary and Outlook FOXO Technologies Inc. plans to expand its Healthcare segment through additional facility acquisitions and service expansion at its BSF campus.The Life Science Services segment aims for growth via organic expansion and complementary acquisitions, while the Labs segment is exploring commercialization opportunities for its epigenetic biomarker technology, including partnerships or a potential sale.The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and insufficient operating cash flow, and plans to submit a new reverse stock split proposal after restructuring with institutional investors to address capital needs. ### Related Stocks - [FOXO.US](https://longbridge.com/en/quote/FOXO.US.md) ## Related News & Research - [FOXO Technologies’ Subsidiary Recognized for Community Impact](https://longbridge.com/en/news/269287497.md) - [FOXO TECHNOLOGIES INC. CEO SEAMUS LAGAN PROVIDES YEAR-END REVIEW TO SHAREHOLDERS | FOXO Stock News](https://longbridge.com/en/news/269723566.md) - [Jim Cramer says the world of tech investing has changed and it's not going back](https://longbridge.com/en/news/287128110.md) - [ZAWYA: Governata Co-Founder appointed President of newly launched La French Tech Riyadh](https://longbridge.com/en/news/287042101.md) - [Vanguard tech ETF backed by strong AI-driven earnings outlook](https://longbridge.com/en/news/286649093.md)